Stay updated on Efgartigimod in Post-COVID-19 POTS Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.

Latest updates to the Efgartigimod in Post-COVID-19 POTS Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedThe Publications section text was updated to clarify PubMed as the source for publications. The page revision number was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check20 days agoChange DetectedThe page shows the removal of a government funding/operating status notice. The core study information, including title, status, enrollment, eligibility, and locations, remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedDifference0.4%

- Check63 days agoChange DetectedMajor update: adds a government funding/operating status notice and updates version to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%

- Check70 days agoChange DetectedAdded a new version label (v3.1.0) and removed several drug-safety related sections (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) indicating a shift in content scope.SummaryDifference0.3%

- Check84 days agoChange DetectedUpdated the page version from v3.0.1 to v3.0.2; the 'Back to Top' control was removed.SummaryDifference0.2%

Stay in the know with updates to Efgartigimod in Post-COVID-19 POTS Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod in Post-COVID-19 POTS Clinical Trial page.